Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL

  • Rivas Delgado, Alfredo|||0000-0003-0385-3415
  • López, Cristina
  • Clot, Guillem|||0000-0003-2588-7413
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Grau Vorster, Marta|||0000-0003-3779-0387
  • Frigola, Gerard|||0000-0001-6794-6456
  • Bosch-Schips, Jan
  • Radke, Josefine
  • Ishaque, Naveed|||0000-0002-8426-901X
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Luizaga Velasco, Luis|||0000-0001-9314-5783
  • Barcena, Carmen
  • Kelleher, Nicholas|||0000-0003-4610-2718
  • Villamor, Neus|||0000-0001-6538-4111
  • Baumann, Tycho|||0000-0003-4421-0088
  • Muntañola, Ana|||0000-0001-7839-6648
  • Sancho-Cia, Juan M.
  • Martín García-Sancho, Alejandro|||0000-0001-6330-1028
  • González Barca, Eva|||0000-0002-1323-1508
  • Matutes, Estella|||0000-0001-6745-7046
  • Brito, Jordi A.
  • Karube, Kennosuke
  • Salaverria Frigola, Itziar|||0000-0002-2427-9822
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Wiemann, Stefan|||0000-0003-4683-3174
  • Heppner, Frank L.
  • Siebert, Reiner
  • Climent, Fina|||0000-0002-4360-8388
  • Campo, Elias|||0000-0001-9850-9793
  • Giné, Eva|||0000-0002-0532-1204
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Bea, Sílvia|||0000-0001-7192-2385
Testicular large B-cell lymphoma (TLBCL) is an infrequent and aggressive lymphoma arising in an immune-privileged site and has recently been recognized as a distinct entity from diffuse large B-cell lymphoma (DLBCL). We describe the genetic features of TLBCL and compare them with published series of nodal DLBCL and primary large B-cell lymphomas of the CNS (PCNSL). We collected 61 patients with TLBCL. We performed targeted next-generation sequencing, copy number arrays, and fluorescent in situ hybridization to assess chromosomal rearrangements in 40 cases with available material. Seventy percent of the cases showed localized stages. BCL6 rearrangements were detected in 36% of cases, and no concomitant BCL2 and MYC rearrangements were found. TLBCL had fewer copy number alterations (p < 0.04) but more somatic variants (p < 0.02) than nodal DLBCL and had more frequent 18q21.32-q23 (BCL2) gains and 6q and 9p21.3 (CDKN2A/B) deletions. PIM1, MYD88, CD79B, TBL1XR1, MEF2B, CIITA, EP300, and ETV6 mutations were more frequent in TLBCL, and BCL10 mutations in nodal DLBCL. There were no major genetic differences between TLBCL and PCNSL. Localized or disseminated TLBCL displayed similar genomic profiles. Using LymphGen, the majority of cases were classified as MCD. However, we observed a subgroup of patients classified as BN2, both in localized and disseminated TLBCL, suggesting a degree of genetic heterogeneity in the TLBCL genetic profile. TLBCL has a distinctive genetic profile similar to PCNSL, supporting its recognition as a separate entity from DLBCL and might provide information to devise targeted therapeutic approaches.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The SOX11:SMARCA4 complex is a driver of oncogenic transcriptional programs in mantle cell lymphoma

  • Bolòs, Anna de
  • Carreras-Caballé, María
  • Sureda-Gómez, Marta
  • Rodríguez, Marta-Leonor
  • Charalampopoulou, Stella
  • Albero Gallego, Robert|||0000-0001-5527-0997
  • Maiques-Diaz, Alba
  • Playa-Albinyana, Heribert
  • Clot, Guillem|||0000-0003-2588-7413
  • López, Cristina
  • Colomer, Dolors|||0000-0001-7486-8484
  • Martin-Subero, José I.
  • Campo, Elias|||0000-0001-9850-9793
  • Reverter Cendrós, David|||0000-0002-5347-0992
  • Villanueva, Josep|||0000-0003-1396-9470
  • Amador, Virginia|||0000-0002-3016-2874
Mantle cell lymphoma (MCL) is considered one of the most aggressive B-cell lymphoid neoplasms. The transcription factor SOX11 is aberrantly expressed in conventional aggressive MCL, while it is not or weakly expressed in the leukemic non-nodal MCL subtype with a predominantly indolent clinical evolution. SOX11 is a key driver of MCL through the regulation of several oncogenic mechanisms, suggesting that it may be interacting with different protein complexes to exert its multiple actions. Using proteomic strategies, we characterized the SOX11-interactome and validated its physical interaction with SMARCA4, the catalytic subunit of the SWI/SNF chromatin-remodeling complex. SMARCA4 expression is directly regulated by SOX11, and its upregulation significantly associates with worse outcomes of patients. Integration of global DNA-binding and transcriptomic profiles revealed that SOX11 and SMARCA4 share binding sites enriched in open chromatin and active promoters and regulate common key oncogenic pathways crucial for MCL progression and aggressiveness. The SMARCA4-specific PROTAC-degrader AU-15330 significantly reduced SOX11 binding to specific regulatory regions and diminished the activation of BCR-, NIK-, and BCL2-signaling pathways. Moreover, SMARCA4 degradation significantly reduced proliferation and induced apoptosis of SOX11-positive MCL cells, highlighting AU-15330 as a promising therapeutic approach for patients who may relapse from current target therapies in MCL. (Figure presented.).
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

  • Syrykh, Charlotte
  • Pons-Brun, Berta
  • Russiñol, Núria
  • Playa-Albinyana, Heribert
  • Baumann, Tycho
  • Duran-Ferrer, Martí
  • Kulis, Marta
  • Carbó-Meix, Anna
  • Mozas, Pablo
  • Alcoceba, Miguel
  • González, Marcos
  • Navarro-Bailón, Almudena
  • Colado, Enrique
  • Payer, Ángel R.
  • Aymerich, Marta
  • Terol, María José
  • Lu, Junyan
  • Knisbacher, Binyamin A.
  • Hahn, Cynthia K.
  • Ruiz-Gaspà, Sílvia
  • Enjuanes, Anna
  • Wu, Catherine J.
  • Getz, Gad
  • Zenz, Thorsten
  • López-Guillermo, Armando
  • Martín-Subero, José Ignacio
  • Colomer, Dolors
  • Delgado, Julio
  • Campo, Elías
  • Nadeu, Ferran
Chronic lymphocytic leukemia (CLL) has high biological and clinical heterogeneity.1,2 A few prognostic factors are used in clinical practice, including immunoglobulin heavy-chain variable (IGHV) gene somatic hypermutation (SHM) status, chromosome aberrations, and gene mutations, which remain insufficient for personalized patient management.3,4 Recent studies have shown that expression of the immunoglobulin lambda light chain IGLV3-21 gene carrying an SHM-derived G>C mutation changing the glycine at position 110 to an arginine (IGLV3-21R110) defines a subset of CLL with an intermediate epigenetic profile and an aggressive clinical course.5,6 When occurring on the IGLV3-21∗01 or ∗04 alleles, the R110 mutation allows homotypic B-cell receptor (BCR) interactions, triggering cell-autonomous BCR signaling5,7 and/or facilitating T-cell–independent engagement with superantigen.8 IGLV3-21R110 has been detected in up to 6.5% of patients with CLL at diagnosis and in up to 25% of patients enrolled in clinical trials.5,6,9 We6 and others5 have shown that all CLL cases belonging to aggressive stereotyped subset #2 carried the IGLV3-21R110. Nonetheless, approximately half of IGLV3-21R110 CLL are not classified as stereotyped subset #2 but seem to have a similar clinical outcome,5,6 suggesting that the conventional stereotyped subset #2 classification might not completely recognize this clinically aggressive subgroup of CLL. In addition, IGLV3-21R110 seems to have a prognostic value independent of the IGHV gene SHM status and methylation–based epigenetic subtypes.5,6 However, further studies in independent cohorts are needed to support its application in clinical practice.1,2,10-12 The aim of this study was to assess the prognostic value of IGLV3-21R110 in large and independent population-based cohorts of patients with CLL., This study was supported by the “la Caixa” Foundation (CLLEvolution - LCF/PR/HR17/52150017 [HR17-00221LCF] and CLLSYSTEMS - LCF/PR/HR22/52420015 [HR22-00172] Health Research 2017 and 2022 Programs; E. Colado), the Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033) and the European Regional Development Fund “Una manera de hacer Europa” (PID2021-123054OB-I00; E. Campo), European Union (EU) NextGenerationEU/Mecanismo para la Recuperación y la Resiliencia and the Instituto de Salud Carlos III (PMP15/00007; E. Campo), the European Research Council under the EU’s Horizon 2020 Research and Innovation Program (810287, BCLLatlas; E. Campo and J.I.M.-S.), the Generalitat de Catalunya Suport Grups de Recerca AGAUR (2017-SGR-1142 and 2021-SGR-01172; E. Campo), the National Institutes of Health/National Cancer Institute grant P01 CA206978 (C.J.W. and G.G.), and the Centro de Investigación Biomédica en Red de Cáncer. H.P.-A. is a recipient of a predoctoral fellowship from the Spanish Ministry of Universities (FPU19/03110). M.D.-F. acknowledges research support from the Asociación Española Contra el Cáncer Scientific Foundation. B.A.K. was supported by a long-term European Molecular Biology Organization fellowship (ALTF 14-2018). C.K.H. was supported by the National Heart, Lung, and Blood Institute Training Program in Molecular Hematology (T32HL116324). F.N. acknowledges research support from the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), European Hematology Association (EHA Junior Research grant 2021, RG-202012-00245), and Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223). E. Campo is an academia researcher of the “Institució Catalana de Recerca I Estudis Avançats” of the Generalitat de Catalunya. This work was partially developed at the Centre Esther Koplowitz (Barcelona, Spain)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Testicular large B-cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL

  • Rivas-Delgado, Alfredo
  • López, Cristina
  • Clot, Guillem
  • Nadeu, Ferran
  • Grau, Marta
  • Frigola, Gerard
  • Bosch-Schips, Jan
  • Radke, Josefine
  • Ishaque, Naveed
  • Alcoceba, Miguel
  • Tapia, Gustavo
  • Luizaga, Luis
  • Barcena, Carmen
  • Kelleher, N.
  • Villamor, Neus
  • Baumann, Tycho
  • Muntañola, Ana
  • Sancho-Cia, Juan M.
  • García-Sancho, Alejandro Martín
  • González-Barca, Eva
  • Matutes, Estella
  • Brito, Jordi A.
  • Karube, Kennosuke
  • Salaverria, Itziar
  • Enjuanes, Anna
  • Wiemann, Stefan
  • Heppner, Frank L.
  • Siebert, Reiner
  • Climent, Fina
  • Campo, Elías
  • Giné, Eva
  • López-Guillermo, Armando
  • Beà, Silvia
Testicular large B‐cell lymphoma (TLBCL) is an infrequent and aggressive lymphoma arising in an immune‐privileged site and has recently been recognized as a distinct entity from diffuse large B‐cell lymphoma (DLBCL). We describe the genetic features of TLBCL and compare them with published series of nodal DLBCL and primary large B‐cell lymphomas of the CNS (PCNSL). We collected 61 patients with TLBCL. We performed targeted next‐generation sequencing, copy number arrays, and fluorescent in situ hybridization to assess chromosomal rearrangements in 40 cases with available material. Seventy percent of the cases showed localized stages. BCL6 rearrangements were detected in 36% of cases, and no concomitant BCL2 and MYC rearrangements were found. TLBCL had fewer copy number alterations (p < 0.04) but more somatic variants (p < 0.02) than nodal DLBCL and had more frequent 18q21.32‐q23 (BCL2) gains and 6q and 9p21.3 (CDKN2A/B) deletions. PIM1, MYD88L265P, CD79B, TBL1XR1, MEF2B, CIITA, EP300, and ETV6 mutations were more frequent in TLBCL, and BCL10 mutations in nodal DLBCL. There were no major genetic differences between TLBCL and PCNSL. Localized or disseminated TLBCL displayed similar genomic profiles. Using LymphGen, the majority of cases were classified as MCD. However, we observed a subgroup of patients classified as BN2, both in localized and disseminated TLBCL, suggesting a degree of genetic heterogeneity in the TLBCL genetic profile. TLBCL has a distinctive genetic profile similar to PCNSL, supporting its recognition as a separate entity from DLBCL and might provide information to devise targeted therapeutic approaches., This study was supported by Fundación Asociación Española Contra el Cancer AECC/CIBER: PROYE18020BEA (S.B.); Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III Instituto de Salud Carlos III, “Cofinanciado por la Unión Europea” and Fondos FEDER: European Regional Development Fund “Una manera de hacer Europa”: PI19/00887 (A.L-G. and E.G.), PI22/00203 (S.B. and E.G.) and INT23/00037 (to S.B.), PI23/01500 (A.L-G.) and INT20/00050 (A.L-G); MCIN/AEI/10.13039/501100011033 and FEDER European Regional Development Fund “Una manera de hacer Europa”: PID2021-123054OB-I00 (E.C.). Marató TV3 TV3-Cancer/201904-30 (S.B.); Generalitat de Catalunya, Suport Grups de Recerca AGAUR: 2021-SGR-01293 (S.B.), 2021-SGR-01274 (E.G.), 2021-SRG-01172 (E.C.). The ICGC MMML-seq Project was supported by the German Ministry of Science and Education (BMBF) in the framework of the ICGC MMML-Seq (01KU1002A-J) and the ICGC DE-Mining (01KU1505G and 01KU1505E). A.R-D is supported by a grant from Fundación Española de Hematología y Hemoterapia. C.L. is supported by a postdoctoral Beatriu de Pinós grant from Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement de la Generalitat de Catalunya and by Marie Sklodowska-Curie COFUND program from H2020 (2018-BP-00055). F.N. is supported by the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), and the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223). M.G. was funded by FPI pre-doctoral fellowship: PRE2019-088443. E.C. is an Academia Researcher of the “Institució Catalana de Recerca i Estudis Avançats” of the Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms

  • Nadeu, Ferran
  • Shuai, Shimin
  • Clot, Guillem
  • Hilton, Laura K.
  • Diaz-Navarro, Ander
  • Martín, Silvia
  • Royo, Romina
  • Baumann, Tycho
  • Kulis, Marta
  • López-Oreja, Irene
  • Cossio, Manuel
  • Lu, Junyan
  • Ljungström, V.
  • Young, Emma
  • Plevova, Karla
  • Knisbacher, Binyamin A.
  • Lin, Ziao
  • Hahn, Cynthia K.
  • Bousquets, Pablo
  • Alcoceba, Miguel
  • González, Marcos
  • Colado, Enrique
  • Payer, Ángel R.
  • Aymerich, Marta
  • Terol, María José
  • Rivas-Delgado, Alfredo
  • Enjuanes, Anna
  • Ruiz-Gaspà, Sílvia
  • Chatzikonstantinou, Thomas
  • Hägerstrand, Daniel
  • Jylhä, Cecilia
  • Skaftason, Aron
  • Mansouri, Larry
  • Stranska, Kamila
  • Doubek, Michael
  • Gastel-Mol, Ellen J. van
  • Davis, Zadie
  • Walewska, Renata
  • Scarfò, Lydia
  • Trentin, Livio
  • Visentin, Andrea
  • Parikh, Sameer A.
  • Rabe, Kari G.
  • Moia, Riccardo
  • Armand, Marine
  • Rossi, Davide
  • Davi, Frédéric
  • Gaidano, Gianluca
  • Kay, Neil E.
  • Shanafelt, Tait D.
  • Ghia, Paolo
  • Oscier, David
  • Langerak, Anton W.
  • Beà, Silvia
  • López-Guillermo, Armando
  • Neuberg, Donna
  • Wu, Catherine J.
  • Getz, Gad
  • Pospisilova, Sarka
  • Stamatopoulos, Kostas
  • Rosenquist, Richard
  • Huber, Wolfgang
  • Zenz, Thorsten
  • Colomer, Dolors
  • Martín-Subero, José Ignacio
  • Delgado, Julio
  • Morin, Ryan D.
  • Stein, Lincoln D.
  • Puente, Xose S.
  • Campo, Elías
Recurrent mutations in the third base of U1 spliceosomal RNA responsible for marked splicing and expression abnormalities have been described in chronic lymphocytic leukemia (CLL) and some solid tumors. However, the clinical significance of these mutations in large and independent CLL cohorts as well as their presence in other B-cell neoplasms is unknown. Here we characterized U1 mutations in 1670 CLL and 363 mature B-cell lymphomas. We confirmed that the g.3A>C U1 mutation is found in 3.5% of CLL, which conferred rapid disease progression independently of the main biological and clinical prognostic markers of the disease. Additionally, a recurrent g.9C>T mutation was found in 1.5% of CLL causing downstream splicing alterations and associated with adverse prognosis. We also identified a g.4C>T mutation in 10% of diffuse large B-cell lymphomas of the germinal center subtype and a g.7A>G mutation in 30% of EBV-negative Burkitt lymphomas, both of which altered the splicing pattern of multiple genes. This study reveals novel, recurrent, and tumor-specific U1 mutations in mature B-cell neoplasms with biological and prognostic implications, thus establishing U1 as a novel pan-B-cell malignancy driver gene., This study was supported by the “la Caixa” Foundation (CLLEvolution - LCF/PR/HR17/52150017 [HR17-00221LCF] and CLLSYSTEMS - LCF/PR/HR22/52420015 [HR22-00172] Health Research 2017 and 2022 Programs, to ECa), the Ministry of Science and Innovation (MCIN)/AEI/10.13039/501100011033 and the European Regional Development Fund (FEDER) “Una manera de hacer Europa” (PID2021-123054OB-I00, to ECa), the National Institute of Health “Molecular Diagnosis, Prognosis, and Therapeutic Targets in Mantle Cell Lymphoma” (P01CA229100 to ECa), Generalitat de Catalunya Suport Grups de Recerca AGAUR (2017-SGR-1142 and 2021-SGR-01172 to ECa), and CERCA Programme-Generalitat de Catalunya (to ECa). FN acknowledges research support from the American Association for Cancer Research (2021 AACR-Amgen Fellowship in Clinical/Translational Cancer Research, 21-40-11-NADE), the European Hematology Association (EHA Junior Research Grant 2021, RG-202012-00245), the Lady Tata Memorial Trust (International Award for Research in Leukaemia 2021-2022, LADY_TATA_21_3223), and Fundación Española de Hematología y Hemoterapia (FEHH) (FEHH_BECAS24_01 co-financed by AstraZeneca). SS was supported by the National Natural Science Foundation of China (Grant No. 82270239 and 32200487), Shenzhen Medical Research Funds (Grant No. A2303044), the Shenzhen Municipal Science and Technology Innovation Council (Grant No. JCYJ20220530115207016), and Center for Computational Science and Engineering at Southern University of Science and Technology (Shenzhen, China). AD-N is supported by the Department of Education of the Basque Government (grant number PRE_2017_1_0100). AR-D was supported by the Fundación Española de Hematología y Hemoterapia (FEHH). KP, KStr, MD, and SP acknowledge financial support from the Ministry of Health of the Czech Republic under the project of the conceptual development of research organization FNBr 65269705 and the project AZV NU21-08-00237, further, they acknowledge support from the Ministry of Education, Youth and Sports of the Czech Republic within the European Regional Development Fund Project “A-C-G-T” No. CZ.02.1.01/0.0/0.0/16_026/0008448 and the National Institute for Cancer Research, Programme EXCELES, No. LX22NPO5102, co-funded by the European Union – Next Generation EU. GGa acknowledges support from AIRC 5 ×1000 project No. 21198, Milan, Italy. PG acknowledges support from Associazione Italiana per la ricerca sul cancro (AIRC) under 5 per Mille 2018—ID. 21198 program—P.I. Roberto Foà, G.L. Paolo Ghia, G. RRos is supported by the Science for Life Laboratory (SciLifeLab), the Swedish Cancer Society, the Swedish Research Council, the Knut and Alice Wallenberg Foundation, Karolinska Institutet, Karolinska University Hospital, and Radiumhemmets Forskningsfonder, Stockholm, Sweden. For patients analyzed at Karolinska Institutet, sequencing was performed by the SNP&SEQ Technology Platform in Uppsala. The facility is part of the National Genomics Infrastructure (NGI) Sweden and SciLifeLab. The SNP&SEQ Platform is also supported by the Swedish Research Council and the Knut and Alice Wallenberg Foundation. SAP, KGR, and NEK acknowledge that the conduct of the Mayo Clinic research was supported in part by the Henry J. Predolin Foundation. XSP is supported by Ministerio de Ciencia e Innovación (PID2020-117185RB-I00) and Fundación Asociación Española Contra el Cáncer (AECC). ECa is an Academia Researcher of the “Institució Catalana de Recerca i Estudis Avançats” (ICREA) of the Generalitat de Catalunya. This work was partially developed at the Centre Esther Koplowitz (CEK, Barcelona, Spain)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Unraveling the genetics of transformed splenic marginal zone lymphoma

  • Grau Vorster, Marta|||0000-0003-3779-0387
  • López, Cristina
  • Navarro, Alba|||0000-0002-4041-0974
  • Frigola, Gerard|||0000-0001-6794-6456
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Clot, Guillem|||0000-0003-2588-7413
  • Bastidas-Mora, Gabriela
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Baptista, Maria Joao|||0000-0003-3471-2535
  • Blanes, Margarita
  • Colomer, Dolors|||0000-0001-7486-8484
  • Costa, Dolors|||0000-0002-8276-3292
  • Domingo-Domenech, Eva|||0000-0001-8907-090X
  • Enjuanes, Anna|||0000-0002-4679-6687
  • Escoda, Lourdes|||0000-0003-3288-9716
  • Forcada, Pilar
  • Giné, Eva|||0000-0002-0532-1204
  • López Guerra, Mónica|||0000-0002-5545-0178
  • Ramón, Olga
  • Rivas Delgado, Alfredo|||0000-0003-0385-3415
  • Folch, Laura Vicente
  • Wotherspoon, Andrew
  • Climent, Fina|||0000-0002-4360-8388
  • Campo, Elias|||0000-0001-9850-9793
  • López Guillermo, Armando|||0000-0002-8588-8381
  • Matutes, Estella|||0000-0001-6745-7046
  • Bea, Sílvia|||0000-0001-7192-2385
The genetic mechanisms associated with splenic marginal zone lymphoma (SMZL) transformation are not well defined. We studied 41 patients with SMZL that eventually underwent large B-cell lymphoma transformation. Tumor material was obtained either only at diagnosis (9 patients), at diagnosis and transformation (18 patients), and only at transformation (14 patients). Samples were categorized in 2 groups: (1) at diagnosis (SMZL, n = 27 samples), and (2) at transformation (SMZL-T, n = 32 samples). Using copy number arrays and a next-generation sequencing custom panel, we identified that the main genomic alterations in SMZL-T involved TNFAIP3, KMT2D, TP53, ARID1A, KLF2, 1q gains, and losses of 9p21.3 (CDKN2A/B) and 7q31-q32. Compared with SMZL, SMZL-T had higher genomic complexity, and higher incidence of TNFAIP3 and TP53 alterations, 9p21.3 (CDKN2A/B) losses, and 6p gains. SMZL and SMZL-T clones arose by divergent evolution from a common altered precursor cell that acquired different genetic alterations in virtually all evaluable cases (92%, 12 of 13 cases). Using whole-genome sequencing of diagnostic and transformation samples in 1 patient, we observed that the SMZL-T sample carried more genomic aberrations than the diagnostic sample, identified a translocation t(14;19)(q32;q13) present in both samples, and detected a focal B2M deletion due to chromothripsis acquired at transformation. Survival analysis showed that KLF2 mutations, complex karyotype, and International Prognostic Index score at transformation were predictive of a shorter survival from transformation (P =.001; P =.042; and P =.007; respectively). In summary, SMZL-T are characterized by higher genomic complexity than SMZL, and characteristic genomic alterations that could represent key players in the transformation event.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

BCL3 rearrangements in B-cell lymphoid neoplasms occur in two breakpoint clusters associated with different diseases

  • Carbo-Meix, Anna
  • Guijarro, Francesca|||0000-0001-6376-0929
  • Wang, Luojun
  • Grau Vorster, Marta|||0000-0003-3779-0387
  • Royo, Romina|||0000-0003-3493-0874
  • Frigola, Gerard|||0000-0001-6794-6456
  • Playa-Albinyana, Heribert
  • Buhler, Marco M.
  • Clot, Guillem|||0000-0003-2588-7413
  • Duran-Ferrer, Marti
  • Lu, Junyan
  • Granada, Isabel|||0000-0002-4275-0104
  • Baptista, Maria Joao|||0000-0003-3471-2535
  • Navarro Ferrando, José Tomás|||0000-0001-9101-6013
  • Espinet Solà, Blanca|||0000-0002-4294-8145
  • Puiggros, Anna|||0000-0001-9627-4978
  • Tapia, Gustavo|||0000-0003-1882-0368
  • Bandiera, Laura
  • De Canal, Gabriella
  • Bonoldi, Emanuela
  • Climent, Fina|||0000-0002-4360-8388
  • Ribera-Cortada, Inmaculada|||0000-0002-3372-828X
  • Fernandez-Caballero, Mariana
  • De la Banda, Esmeralda
  • Do Nascimento, Janilson
  • Pineda, Alberto
  • Vela, Dolors
  • Rozman, Maria|||0000-0002-2641-1110
  • Aymerich, Marta
  • Syrykh, Charlotte
  • Brousset, Pierre
  • Perera, Miguel
  • Yáñez, Lucrecia|||0000-0001-9925-3048
  • Ortin, Jesus Xavier
  • Tuset, Esperanza|||0000-0002-1463-6689
  • Zenz, Thorsten|||0000-0001-7890-9845
  • Cook, James R.
  • Swerdlow, Steven H.
  • Martin-Subero, Jose I.
  • Colomer, Dolors|||0000-0001-7486-8484
  • Matutes, Estella|||0000-0001-6745-7046
  • Bea, Silvia
  • Costa, Dolors|||0000-0002-8276-3292
  • Nadeu, Ferran|||0000-0003-2910-9440
  • Campo, Elias|||0000-0001-9850-9793
The t(14;19)(q32;q13) often juxtaposes BCL3 with immunoglobulin heavy chain (IGH) resulting in overexpression of the gene. In contrast to other oncogenic translocations, BCL3 rearrangement (BCL3-R) has been associated with a broad spectrum of lymphoid neoplasms. Here we report an integrative whole-genome sequence, transcriptomic, and DNA methylation analysis of 13 lymphoid neoplasms with BCL3-R. The resolution of the breakpoints at single base-pair revealed that they occur in two clusters at 5' (n=9) and 3' (n=4) regions of BCL3 associated with two different biological and clinical entities. Both breakpoints were mediated by aberrant class switch recombination of the IGH locus. However, the 5' breakpoints (upstream) juxtaposed BCL3 next to an IGH enhancer leading to overexpression of the gene whereas the 3' breakpoints (downstream) positioned BCL3 outside the influence of the IGH and were not associated with its expression. Upstream BCL3-R tumors had unmutated IGHV, trisomy 12, and mutated genes frequently seen in chronic lymphocytic leukemia (CLL) but had an atypical CLL morphology, immunophenotype, DNA methylome, and expression profile that differ from conventional CLL. In contrast, downstream BCL3-R neoplasms were atypical splenic or nodal marginal zone lymphomas (MZL) with mutated IGHV, complex karyotypes and mutated genes typical of MZL. Two of the latter four tumors transformed to a large B-cell lymphoma. We designed a novel fluorescence in situ hybridization assay that recognizes the two different breakpoints and validated these findings in 17 independent tumors. Overall, upstream or downstream breakpoints of BCL3-R are mainly associated with two subtypes of lymphoid neoplasms with different (epi)genomic, expression, and clinicopathological features resembling atypical CLL and MZL, respectively.